This study expands this line of research on the role of cPLA2 in AD pathology by demonstrating the involvement of oTau-activated cPLA2 in altering membrane function through its effect on downregulating Cav-1, a membrane protein known to stabilize lipid rafts, leading to a disruption of insulin signaling. Here, PLA2G4A is linked to Alzheimer disease.